electroCore is a medical technology company developing non-invasive neuromodulation therapies. The company's flagship product, gammaCore, is a transcutaneous vagus nerve stimulation (tVNS) device approved for episodic cluster headache and being investigated for other neurological conditions including Parkinson's disease[1].
| Attribute | Value |
|---|---|
| Founded | 2005 |
| Headquarters | Basking Ridge, New Jersey, USA |
| Stock | NASDAQ: ECOR |
| Focus | Non-invasive vagus nerve stimulation (tVNS) |
| Stage | Commercial + clinical development |
| Website | electrocore.com |
electroCore was founded to develop non-invasive neuromodulation technologies based on proprietary vagus nerve stimulation technology. The company's approach allows for transcutaneous (through the skin) stimulation of the vagus nerve, avoiding the need for surgical implantation required by traditional vagus nerve stimulation devices.
The company's name reflects its core technology—"electro" refers to electrical stimulation, and "core" represents the central role of the vagus nerve in modulating various physiological systems.
electroCore is a publicly traded company (NASDAQ: ECOR) focused on advancing tVNS therapy across multiple neurological and autonomic conditions.
gammaCore is a handheld, prescription-only transcutaneous vagus nerve stimulation (tVNS) device:
The gammaCore device works through several mechanisms relevant to Parkinson's disease:
electroCore is actively investigating tVNS for Parkinson's disease:
Mechanistic rationale: Multiple studies suggest VNS may improve motor function in PD through:
Clinical evidence: Several clinical trials have explored tVNS in PD, with some showing improvements in:
Ongoing trials: Additional trials are evaluating tVNS as a potential treatment for PD motor symptoms and non-motor manifestations
| Indication | Development Stage | Status |
|---|---|---|
| Episodic cluster headache | FDA-cleared | Commercial |
| Parkinson's disease | Clinical development | Investigational |
| Epilepsy | Clinical development | Investigational |
| Migraine | Clinical development | Investigational |
| Tinnitus | Clinical development | Investigational |
| Insomnia | Preclinical/Clinical | Investigational |
electroCore operates in the non-invasive neuromodulation space:
Competitors in the neuromodulation space include:
Key developments for electroCore include:
electroCore Company Overview. 2024. ↩︎